Forbes article regarding 60 minutes last night on high cancer drug costs
Tig said
Oct 6, 2014
Isiscat2011 wrote:
Gator Man wrote:
The discussion is equally valid for new hepatitis c drug costs. A good article that examines the paradox we now have with pharmaceutical companies and their justification for super expensive drugs. The costs may be fair given the results, but does it matter if the price structure puts them out of reach?
Exactly. This is the time for Pharma to self-regulate by establishing reasonable costs. They can be reasonable and still make plenty of dough. If they don't self-regulate it will be done for them.
We'll have to wait and see what happens in the near future hopefully. I wish our individual complaints were more effective, if they were, this forum would glow. But we can keep trying though! Be sure and take the time to contact the congressional officials in your state or the government officials in your country/location. Here in the US, you can find the contact information for your elected officials here: http://www.contactingthecongress.org/
Tig
Isiscat2011 said
Oct 6, 2014
Gator Man wrote:
The discussion is equally valid for new hepatitis c drug costs. A good article that examines the paradox we now have with pharmaceutical companies and their justification for super expensive drugs. The costs may be fair given the results, but does it matter if the price structure puts them out of reach?
Exactly. This is the time for Pharma to self-regulate by establishing reasonable costs. They can be reasonable and still make plenty of dough. If they don't self-regulate it will be done for them.
pl1952 said
Oct 6, 2014
Gator Man, that was an excellent piece on 60 Minutes last nite! Here's the link for 60 minutes:
"The examples used in Stahls story tonight were a year or two old. But in my business we often think of the moment when a story hits 60 Minutes as peak hype. It might be time for drug industry executives to think out loud about how to decide what will limit cancer drug costs, and when costs should be high before someone else does that thinking for them. With Merck, AstraZeneca, and Roche all making high-priced, high-value cancer drugs central to their business plans, this is a major issue."
The discussion is equally valid for new hepatitis c drug costs. A good article that examines the paradox we now have with pharmaceutical companies and their justification for super expensive drugs. The costs may be fair given the results, but does it matter if the price structure puts them out of reach?
We'll have to wait and see what happens in the near future hopefully. I wish our individual complaints were more effective, if they were, this forum would glow. But we can keep trying though! Be sure and take the time to contact the congressional officials in your state or the government officials in your country/location. Here in the US, you can find the contact information for your elected officials here: http://www.contactingthecongress.org/
Tig
Exactly. This is the time for Pharma to self-regulate by establishing reasonable costs. They can be reasonable and still make plenty of dough. If they don't self-regulate it will be done for them.
Gator Man, that was an excellent piece on 60 Minutes last nite! Here's the link for 60 minutes:
http://www.cbsnews.com/news/the-cost-of-cancer-drugs/
"The examples used in Stahls story tonight were a year or two old. But in my business we often think of the moment when a story hits 60 Minutes as peak hype. It might be time for drug industry executives to think out loud about how to decide what will limit cancer drug costs, and when costs should be high before someone else does that thinking for them. With Merck, AstraZeneca, and Roche all making high-priced, high-value cancer drugs central to their business plans, this is a major issue."
http://www.forbes.com/sites/matthewherper/2014/10/05/60-minutes-just-attacked-high-drug-prices-heres-what-you-should-know/
The discussion is equally valid for new hepatitis c drug costs. A good article that examines the paradox we now have with pharmaceutical companies and their justification for super expensive drugs. The costs may be fair given the results, but does it matter if the price structure puts them out of reach?